Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.
Dispatch Bio has raised $216.0M in total funding. The most recent round was Series A. The last funding was announced in July 2025.
Dispatch Bio's investors include ARCH Venture Partners, Bristol-Myers Squibb, Alexandria Venture Investments, University of Pennsylvania, Stanford University.
Dispatch Bio is headquartered in Philadelphia, United States.
Dispatch Biotherapeutics develops immunotherapy that treats solid tumors, which could significantly advance cancer treatment options.
Dispatch Bio is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Dispatch Bio — Funding & Investors." VCBacked, July 23, 2025, https://www.vcbacked.co/company/dispatch-bio. Accessed July 21, 2026.
VCBacked. (2025). Dispatch Bio — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/dispatch-bio
{{cite web |title=Dispatch Bio — Funding & Investors |url=https://www.vcbacked.co/company/dispatch-bio |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated